Health canada accepts valneva's chikungunya vaccine license application for review

Saint - herblain ( france), august 29 , 2 02 3 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that health canada has completed screening validation of the company's regulatory application for marketing approval of its single-shot chikungunya vaccine candidate vla1553 in persons aged 18 years and above, and has determined that the new drug submission (nds) application is sufficiently complete to permit a substantive review. based on health canada's performance standard to process an nds application, the company believes the regulatory review could be completed by mid-2024.
VALN Ratings Summary
VALN Quant Ranking